Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 2 |
| 1.1 List of Tables | 3 | 1 |
| 1.2 List of Figures | 3 | 1 |
| 2 Introduction | 3 | 2 |
| 2.1 What Is This Report About? | 4 | 1 |
| 2.2 Definitions of Markets Covered in the Report | 4 | 1 |
| 3 Micro-Electromechanical Sensors Market, Australia | 5 | 6 |
| 3.1 Micro-Electromechanical Sensors Market, Australia, Revenue ($m), 2008-2015 | 5 | 1 |
| 3.2 Micro-Electromechanical Sensors Market, Australia, Revenue ($m), 2015-2022 | 6 | 1 |
| 3.3 Micro-Electromechanical Sensors Market, Australia, Volume (Units), 2008-2015 | 7 | 1 |
| 3.4 Micro-Electromechanical Sensors Market, Australia, Volume (Units), 2015-2022 | 8 | 1 |
| 3.5 Micro-Electromechanical Sensors Market, Australia, Average Price ($), 2008-2022 | 9 | 1 |
| 3.6 Micro-Electromechanical Sensors Market, Australia, Distribution Share by Revenue ($m), 2014-2015 | 10 | 1 |
| 4 Micro-Electromechanical Sensors Market Pipeline Products | 11 | 1 |
| 5 Financial Deals Landscape | 12 | 4 |
| 5.1 Equity Offerings | 12 | 1 |
| 5.1.1 ImpediMed Raises USD25.2 Million in Second and Final Tranche of Private Placement of Shares | 12 | 2 |
| 5.1.2 ImpediMed Raises Funds in Share Purchase Plan | 14 | 1 |
| 5.1.3 ImpediMed Raises USD30 Million in First Tranche of Private Placement of Shares | 15 | 1 |
| 6 Recent Developments | 16 | 4 |
| 6.1 Corporate Communications | 16 | 1 |
| 6.1.1 Feb 29, 2016: Impedimed Announces Changes To The Board Of Directors | 16 | 1 |
| 6.2 Financial Announcements | 16 | 1 |
| 6.2.1 Aug 08, 2016: ImpediMed Changes to Board of Directors | 16 | 1 |
| 6.2.2 Feb 24, 2016: ImpediMed: Half-Year Results Ended 31 December 2015 | 17 | 1 |
| 6.3 Government and Public Interest | 18 | 1 |
| 6.3.1 Aug 09, 2016: FDA Releases Important Information Focused on Digital Health | 18 | 1 |
| 6.4 Other Significant Developments | 18 | 1 |
| 6.4.1 Sep 23, 2016: Safety Review Committee supports dose escalation with Betalutin in Lymrit 37-01 trial pending safety data from cohort receiving higher pre-dosing | 18 | 2 |
| 7 Appendix | 20 | 5 |
| 7.1 Research Methodology | 21 | 3 |
| 7.1.1 Coverage | 21 | 1 |
| 7.1.2 Secondary Research | 21 | 1 |
| 7.1.3 Primary Research | 22 | 1 |
| 7.1.4 Company Share Analysis | 22 | 1 |
| 7.1.5 Distribution Share Analysis | 22 | 1 |
| 7.1.6 Benchmarking | 23 | 1 |
| 7.2 GlobalData Consulting | 23 | 1 |
| 7.3 Contact Us | 23 | 1 |
| 7.4 Disclaimer | 24 | 1 |